Document is current
Any future updates will be listed below
-
Authors
Kistler-Fischbacher, Melanie https://orcid.org/0000-0001-7783-5872
Gohar, Ghazala
de Godoi Rezende Costa Molino, Caroline https://orcid.org/0000-0001-6925-1201
Geiling, Katharina
Meyer-Heim, Tatjana
Kressig, Reto W. https://orcid.org/0000-0002-3215-7681
Orav, E. John
Vellas, Bruno
Guyonnet, Sophie
da Sliva, José A.P. https://orcid.org/0000-0002-2782-6780
Rizzoli, René https://orcid.org/0000-0002-1537-422X
Armbrecht, Gabriele https://orcid.org/0000-0002-6578-338X
Steinhagen-Thiessen, Elisabeth
Egli, Andreas https://orcid.org/0000-0001-5809-4167
Bischoff-Ferrari, Heike A. https://orcid.org/0000-0002-4554-658X
-
Funding
Funding for this research was provided by:
University of Zurich
- License Information
-
More Information
Article History
Received: 9 July 2024
Accepted: 29 January 2025
First Online: 17 March 2025
Declarations
:
: HAB-F reports as the PI of the DO-HEALTH trial, grants from the European Commission (Grant Agreement No. 278588), from the University of Zurich, from NESTEC, from PFIZER Consumer Healthcare, from Streuli Pharma, plus non-financial support from DSM Nutritional Products and from Roche Diagnostics. Furthermore, HAB-F reports speaker fees from Wild, Pfizer, Vifor, Mylan, Roche Diagnostics, and independent and investigator initiated grants from Pfizer and from Vifor, outside the submitted work. BV declares participation in the following advisory boards: Biogen, Alzheon, Norvo Nordisk, Lilly, Eisai France and International, Roche, TauX and Cerecin. JAPD declares honoraria from Amgen and Fresenius-Kabi and support meetings/travels from MedacAP. TM-H declares speaker fees from OM pharma. MK-F, GG, CG, KG, RWK, EJO, SG, GA, RR, GA, ES-T, AE, declare no conflict of interest.
